reason report
track pt
bottom line top-line data catalyst clinic trial still
track expect momentum continu
despit share strong sinc posit
advoc avacopan anca-associ vasculitis/aav data place
investor radar link despit challeng
management reiter top-line data readout remain schedul
first readout sub-
nephrot focal segment glomerulosclerosis/fsg could unlock
valu second clinic candid inhibitor
meanwhil remain track submit avacopan nda aav
end quarter cash believ
well posit fund oper anticip data
readout beyond reiter op rais pt
come closer view recal guid
meaning data readout across clinic trial term
compani announc today remain
track potenti de-risk mileston start top-line result
studi sub-nephrot focal segment
glomerulosclerosi fsg line aurora
avacopan hidraden suppurativa/h report today
trial complet enrol target pt target vs pt
enrol trial power show differ
hiscr hidraden suppurativa clinic respons
arm placebo pt management believ studi adequ
power show clinic meaning chang hiscr
trial seen notabl placebo effect util endpoint believ
size trial random across placebo
dose group may work favor demonstr clearer
separ placebo drug effect see thought
pend posit data believ oral avacopan could take meaning
share hs market aurora top-line result remain track
accolad avacopan complement glomerulopathy/
nephrot fsg expect
back half year
remain track aav nda file recal
report strongli posit advoc data avacopan
aav sent stock back novemb link sinc
announc advoc hit primari endpoint well
deliv multipl secondari endpoint dilig
work prepar avacopan nda submiss today management reiter
guidanc nda submiss follow submiss
blend revenu multipl
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
ema partner vifor pharma later year conjunct
nda prepar work build commerci
oper ahead potenti launch management note today
call field sale forc suffici effect
commerci avacopan target rheumatologist
nephrologist account us market addit
advoc data includ detail subgroup analys expect
announc upcom eular european congress
rheumatolog june era-edta european renal
association-european dialysi transplant associ june
updat model reflect financi
end cash report ep
accord management cash guidanc assumpt
continu spend salesforc buildout ahead potenti
commerci launch project cash runway suffici fund
ccxi oper updat model reflect
financi well modifi discount termin growth
rate line similar stage compani coverag univers
total chang rais one-year pt
rate share outperform clinical-stag biotechnolog compani leverag
oral administ small molecul inhibit chemokin chemoattract receptor much
ccxi valuat hing lead compound avacopan formerli potent inhibitor
receptor evalu multipl mid-to-l stage clinic trial
see posit advoc data anca-associ vascul aav de-risk
asset well valid druggabl target behind aav potenti posit outcom
follow-on indic glomerulopathi hidraden suppurativa hs may
render avacopan pipelin within drug despit mani uncertainti unknown
complement biolog believ alxn op success set import preced
sinc chemokin complement system far-reach implic human health
avacopan success could lead posit read-through ccxi earlier-stag asset
asset long term de-risk avacopan could
lead investor appreci ccxi proprietari platform may eventu tap
preval competit indic inflammatori bowel diseas ibd oncolog
valuat limit ccxi orphan program
deriv one-year pt base blend dcf analysi revenu
multipl analysi assign valu probability-weight sale avacopan po
anca-associ vascul aav glomerulopathi hidraden
suppurativa hs sale po focal segment glomerulosclerosi
fsg addit indic clinic asset earlier-stag candid
repres upsid estim matur clinical-stag compani de-risk aav
program use discount rate termin growth rate impli market cap
clinical-stag compani risk includ clinic regulatori financi
lead asset avacopan add signific binari risk head data readout even
though evalu multipl indic guarante program
understand complement system diseas still evolv success
particular indic may translat success indic
clinic risk associ clinic candid
collabor licens revenu
total incom expens
chang cash
proce common stock
proce convert note/debt
proce warrant
discount rate/cost equiti
